TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism.
Roca Suarez AA, Plissonnier ML, Grand X, Michelet M, Giraud G, Saez-Palma M, Dubois A, Heintz S, Diederichs A, Van Renne N, Vanwolleghem T, Daffis S, Li L, Kolhatkar N, Hsu YC, Wallin JJ, Lau AH, Fletcher SP, Rivoire M, Levrero M, Testoni B, Zoulim F.
Roca Suarez AA, et al. Among authors: wallin jj.
Gut. 2024 Nov 11;73(12):2012-2022. doi: 10.1136/gutjnl-2023-331396.
Gut. 2024.
PMID: 38697771
Free article.